| | | | | | |

Preventing New Tumor “Seeding” After Mesothelioma Biopsy

2313161_surgeon4Doctors in England are testing a method they hope will reduce the likelihood of pleural mesothelioma patients developing new tumors in their chest wall after a biopsy.

A tissue sample is required to make a definitive mesothelioma diagnosis.

But as many as 15 percent of mesothelioma patients who undergo some kind of invasive biopsy procedure will develop tiny new tumors along the tracks of the intervention site.

Now, doctors at medical centers across England are performing the first randomized trial of prophylactic irradiation of those intervention sites as a way of preventing new mesothelioma tumors.

Mesothelioma Biopsy Options

There is no blood test for mesothelioma. Instead, patients suspected of having the asbestos cancer will undergo a thorough exam, a health and work history, imaging studies and, usually, a procedure to remove some cells from the suspected mesothelioma tumor site.

There are several methods that can be used to obtain mesothelioma cells for biopsy. If the tumor is small, a CT-guided needle biopsy may be used. Other options include video-assisted thoracoscopic surgery (VATs), thoracoscopy, or open thoracotomy.

Unfortunately, all of these invasive procedures have been linked to the “seeding” of new mesothelioma tumors, especially along the tracks where the needles or other instruments are inserted.

Preventing New Mesothelioma Tumors

The answer to preventing new mesothelioma tumors after a biopsy procedure may be to irradiate those areas before there are any new signs of mesothelioma.

Although this prophylactic irradiation, also known as PIT, is regularly used as a way to treat mesothelioma tumor seeding, there has never been a formal, randomized study of the practice to find out how well it actually works.

PIT in Mesothelioma Treatment

To test the effectiveness of PIT in preventing new mesothelioma tumors after biopsy, doctors at more than half a dozen English hospitals have randomly assigned 374 mesothelioma patients to either receive PIT or not.

For those who will be receiving PIT, it will be given in three fractions of 21 Gy each. Subsequent mesothelioma treatment, such as chemotherapy, is up to the patients’ oncologists.

Researchers are hoping to be able to show a reduction in the number of new mesothelioma tumors springing up after biopsy.

“A reduction in the incidence of chest wall nodules from 15% to 5% in favour of radiotherapy 6 months after randomization would be clinically significant,” writes investigator Dr. Neil Bayman, an oncologist with the Christie Hospital NHS Foundation Trust in Manchester.

The study finished recruiting new patients in December. Participating mesothelioma patients will be followed for 6 months for evidence of new chest wall nodules. Results should be available in late 2016.

Source:

Bayman, N et al, “Protocol for PIT: a phase III trial of propnhylactice irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention”, January 27, 2016

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…